Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19426813 | 1.00 | KMT2A (0.60) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31135499 | 1.00 | KMT2A (0.60) | KMT2ACASP3EPHX2MDM4TP53 | |
| Hydrochloric Acid SCHEMBL30293185 | 0.99 | KMT2A (0.59) | KMT2ACASP3EPHX2MDM4TP53 | |
| Hydrochloric Acid SCHEMBL31373834 | 0.99 | KMT2A (0.59) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL21504341 | 0.90 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL29400279 | 0.88 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL29401663 | 0.88 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12714718 | 0.88 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31520526 | 0.88 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12292171 | 0.88 | KMT2A (0.54) | KMT2ACASP3EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023039068-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PEPTIDE NUCLEIC ACID INTERMEDIATES | NEUBASE THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |